엔컴퍼스 헬스(EHC) 2026년 3분기 실적 발표 콘퍼런스 콜: EBITDA 15.5% 증가하며 가이던스 상향

주요 요약

• 2026년 3분기 매출액은 퇴원 환자 수가 5.7% 증가하고 퇴원 환자당 순매출액이 4.0% 늘어난 데 힘입어 전년 동기 대비 8.9% 증가했습니다.
• 조정 EBITDA는 3억 4,660만 달러로 15.5% 증가했으며, 조정 EPS는 23.6% 올랐습니다. 경영진은 2026년 전체 실적 가이던스를 다시 상향 조정했습니다.
• 환자의 중증도 상승이 퇴원 환자당 순매출액 증가를 견인했습니다. 성장은 신경계 질환, 뇌졸중, 뇌손상, 중증 외상 분야에 집중된 반면, 하지 관절 치환술은 감소했습니다.
• 인력 관련 동향은 계속 양호한 모습을 보였습니다. 프리미엄 인건비는 390만 달러 줄어든 2,310만 달러를 기록하며 16분기 연속 전년 동기 대비 감소세를 이어갔습니다. 파견 인력 비율은 전체 FTE(전업 대응 인력)의 0.9%를 차지했습니다.
• 엔컴패스 헬스는 병상 수 확장을 지속했습니다. 3분기까지 총 189병상 규모의 신규 병원 4곳을 개원했고, 기존 병원에 85개 병상을 추가했습니다. 2026년 이후 발표된 파이프라인에는 15개 병원과 654개 병상이 포함되어 있습니다.
• 청구 시스템 전환 여파로 3분기 대손상각비 비율이 2.7%로 상승했습니다. 경영진은 4분기에 이 비율이 2.0%~2.5% 수준으로 정상화될 것으로 예상하고 있습니다.

주요 재무 데이터

사업 및 영업 실적

입원 재활 치료에 대한 수요는 견조하게 유지되었습니다. 3분기 퇴원 환자 수 증가율은 5.7%에 달했으며, 환자 구성은 더 높은 중증도 진단군으로 이동했습니다. 동일 병원 기준 환자 수는 신경 재활 9.3%, 뇌졸중 5.1%, 뇌손상 5.7%, 중증 외상 10.3% 증가한 반면, 하지 관절 치환술은 5.3% 감소했습니다.

회사는 2026년 1~9월 동안 37,620명의 뇌졸중 환자를 치료했으며, 이는 전체 환자 구성의 약 18%를 차지합니다. 3분기 품질 지표로는 가정/지역사회 복귀율 84.7%, 급성기 병원 이송률 8.4%, 전문간호시설 이송률 6.2%를 기록했습니다.

병상 용량 투자는 여전히 성장 전략의 핵심으로 유지되었습니다. 엔컴패스 헬스는 3분기 중 펜실베이니아주 노리스타운에 50병상 규모 병원을 개원했으며, 기존 병원들에 31개 병상을 추가했습니다. 10월에는 메인주 뱅거와 텍사스주 샌안토니오에 50병상 규모 병원 2곳을 추가 개원하는 한편, 기존 시설에 60개 병상을 확충했습니다.

2026년 남은 기간 동안 경영진은 총 100병상 규모의 병원 2곳을 추가 개원하고, 기존 병원에 최대 45개 병상을 확충할 계획입니다. 또한 2027년에는 기존 병원에 150~200개 병상을 추가할 것으로 예상하고 있습니다.

10월 1일 노스캐롤라이나주의 필요증명서(Certificate of Need) 법이 폐지됨에 따라 이 지역 역시 주요 개발 거점으로 떠올랐습니다. 엔컴패스 헬스는 15개 시장을 우선순위로 선정했으며 6개 부동산 부지에 대해 계약을 체결한 상태입니다.

제향군인회(VA) 관련 환자 수는 3분기에 21% 증가해 6분기 연속 20% 이상의 성장률을 기록하며 성장 동력 역할을 지속했습니다. 경영진은 VA 관련 사업이 여러 지역 및 병원 전반에서 추가적인 침투 잠재력을 계속 제공하고 있다고 밝혔습니다.

경영진 실적 가이던스

엔컴패스 헬스는 2026년 전체 실적 가이던스를 상향 조정했습니다.

경영진은 현재 2026년 순개원 사전 비용 및 램프업(가동 초기) 비용을 2,000만~2,400만 달러로 예상하고 있습니다. 또한 플로리다주의 2026 회계연도 메디케이드 주 정부 지시 지불 프로그램에 대한 CMS 승인이 계속 계류 중임에 따라 조정 EBITDA에 대한 예상 순의료제공자세 기여액을 약 300만 달러로 하향 조정했습니다.

4분기 중 플로리다주의 제안서가 제출된 면제 조항과 함께 승인될 경우, EBITDA에 미칠 잠재적 긍정적 영향은 약 800만 달러가 될 것이라고 경영진은 설명했습니다.

2027년에 대해 회사는 공식 가이던스를 제시하지 않았습니다. 경영진은 다시 한 번 견조한 한 해를 보낼 수 있는 여건이 조성되고 있다고 언급하며, 개원 사전 비용 및 램프업 비용을 약 2,000만 달러 안팎으로 추정했습니다.

리스크 및 주요 관전 포인트

• 플로리다주 보조금 지불: 주 회계연도 종료 시점까지 CMS가 플로리다주의 2026 회계연도 프로그램을 승인하지 않았습니다. 엔컴패스 헬스는 3분기에 계상된 보조금 지불 매출액 920만 달러와 관련 의료제공자세 비용 340만 달러를 환입 처리했습니다.
• 청구 시스템 전환: Patcom에서 오라클(Oracle)로의 시스템 전환으로 인해 기존 청구 건, 특히 민간 관리 의료 및 메디케어 어드밴티지의 처리 지연이 발생했습니다. 경영진은 연말까지 밀린 청구 건이 해소될 것으로 예상하고 있습니다.
• RCD 확대: 75개 병원이 사전심사제도(Review Choice Demonstration, RCD) 요건에 추가로 포함될 예정입니다. 경영진의 주요 관심사는 팰메토(Palmetto)가 이전 RCD 처리 물량의 10배가 넘는 건수를 효율적으로 처리할 수 있는지 여부입니다.
• 병상 가동률 제약: 3분기 중 58개 병원이 90% 이상의 가동률로 운영되었으며, 평균 가동률은 95%에 달했습니다. 1~3분기 내내 이 그룹에 유지되었던 49개 병원 중 19개 병원은 2027년 말까지 병상 추가가 예정되어 있습니다.
• 수가 비교: 높은 중증도가 퇴원 환자당 순매출액을 계속 지원하고 있으나, 경영진은 2025년 4분기에 더욱 두드러졌던 중증도 관련 증가세의 기저 효과가 작용함에 따라 전년 동기 대비 성장세가 둔화될 수 있다고 언급했습니다.

애널리스트 Q&A 주요 내용

• 메디케어 어드밴티지 이의 신청: 입원 및 이의 신청 시범 프로그램을 통해 294건의 청구를 처리했으며, 이 중 87%가 엔컴패스 헬스 측에 유리하게 판결되었고 81%는 행정법 판사 단계에 이르기 전에 해결되었습니다. 회사는 이 시범 프로그램을 9개에서 13개 병원으로 확대했으며 모든 병원 및 지불자 대상의 뇌졸중 케이스로 이 방식을 확장하고 있습니다.
• 소형 병원 모델: 경영진은 최초의 소형 병원이 2027년 말에 개원할 것으로 기대하고 있습니다. 회사는 병상당 약 100만 달러의 건설 비용을 추산하며, 기존 신규 병원 설립(de novo)과 병상 증설의 중간 수준인 약 20%의 내부수익률(IRR)을 목표로 하고 있습니다.
• 개발 기회: 운영진과 개발팀은 약 200곳의 소형 병원 입지 후보지를 발굴했습니다. 경영진은 인허가 템플릿이 수립된 후 2028년과 2029년에 이 모델의 확장이 가속화될 것으로 예상하고 있습니다.
• 신규 병원 가동 안착: 최근 개원한 신규 병원들은 대체로 개원 6개월 차 무렵에 자체 독자 EBITDA(four-wall EBITDA) 흑자를 달성하고, 10개월 차 무렵에는 70% 이상의 병상 가동률을 기록했습니다. 경영진은 현재 개원 중인 병원 그룹도 유사한 패턴을 보일 것으로 예상합니다.
• 자본 배분: 순레버리지 비율이 1.8배 수준을 기록함에 따라, 경영진은 신규 병상 용량에 대한 지속적인 투자, 완만한 정기 배당금 인상, 추가 자사주 매입 여력이 확보될 것으로 기대하고 있습니다.
• RCD 수익성 및 절차: 경영진은 첫 RCD 주기 동안 80% 승인 목표를 초과 달성한 병원이 7월 1일부터 5% 무작위 표본 점검 옵션 대상이 되어 초기 심사 기간 이후 행정적 부담이 경감될 것으로 예상하고 있습니다.

실적발표 컨퍼런스 콜 전문

---

전체 실적 발표 컨퍼런스 콜 녹취록

경영진 발표

Operator

Good morning, everyone, and welcome to Encompass Health's Third Quarter 2026 Earnings Conference Call. [Operator Instructions] Today's conference call is being recorded. If you have any objections, you may disconnect at this time. I will now turn the call over to Mark Miller, Encompass Health's Chief Investor Relations Officer.

Mark Miller

Thank you, operator, and good morning, everyone. Thank you for joining Encompass Health's Third Quarter 2026 Earnings Call. Before we begin, if you do not already have a copy, the third quarter earnings release, supplemental information and related Form 8-K filed with the SEC are available on our website at encompasshealth.com.

On Page 2 of the supplemental information, you will find the safe harbor statements, which are also set forth in greater detail on the last page of the earnings release. During the call, we will make forward-looking statements, such as guidance and growth projections, which are subject to risks and uncertainties, many of which are beyond our control. Certain risks and uncertainties, like those relating to regulatory developments as well as volume, bad debt and cost trends that could cause actual results to differ materially from our projections, estimates and expectations are discussed in the company's SEC filings, including the earnings release and related Form 8-K, the Form 10-K for the year ended December 31, 2025, and the Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026, when filed.

We encourage you to read them. You are cautioned not to place undue reliance on the estimates, projections, guidance and other forward-looking information presented, which are based on current estimates of future events and speak only as of today. We do not undertake a duty to update these forward-looking statements. Our supplemental information and discussion on this call will include certain non-GAAP financial measures. For such measures, reconciliation to the most directly comparable GAAP measure is available at the end of the supplemental information, at the end of the earnings release and as part of the Form 8-K filed yesterday with the SEC, all of which are available on our website.

I would like to remind everyone that we will adhere to the 1 question and 1 follow-up question rule to allow everyone to submit a question. If you have additional questions, please feel free to put yourself back in the queue. With that, I'll turn the call over to President and Chief Executive Officer, Mark Tarr.

Mark Tarr

Mark, thank you, and good morning, everyone. We're very pleased with our third quarter results. As revenue grew 8.9%, adjusted EBITDA increased 15.5% and adjusted EPS increased 23.6%. For the first 9 months of 2026, revenue rose 9.2%, adjusted EBITDA increased 11.9% and adjusted EPS was up 17%.

Based primarily on our Q3 results, we are again raising our guidance for 2026. We achieved these results while once again delivering outstanding patient outcomes. Our Q3 discharge to community rate was 84.7%, discharge to acute rate was 8.4% and discharge to SNF rate was 6.2%.

Our performance on each of these quality metrics continues to exceed industry averages. Our hospitals continue to be recognized for the outstanding clinical care we provide. Newsweek recently named Encompass Health as America's most awarded leader in inpatient rehabilitation for the seventh consecutive year.

Also, NRC Health, a leading provider of patient experience data, recognized Encompass Health with the 2026 NRC Health Excellence and Patient Experience Award for the second consecutive year, placing us among the top 3 large health systems nationwide for patient experience. Our investments in professional growth and development programs for our clinicians continue to enhance our abilities to serve high-acuity medically complex patients.

Encompass Health holds 408 Joint Commission disease-specific certifications, including 150 Joint Commission stroke certifications. This represents approximately 65% of total stroke certifications among all providers. In August 2026, the American Heart Association and American Stroke Association reaffirmed the importance of inpatient rehabilitation facilities in their updated 2026 stroke rehabilitation guideline, recommending IRF care over skilled nursing facilities for eligible stroke patients when both settings are available.

The recommendation is supported by evidence showing greater functional improvement and higher rates of discharge back to the community following IRF care. We treat more stroke patients than any other inpatient rehabilitation provider. Through the first 3 quarters of 2026, we treated 37,620 patients recovering from a stroke, comprising approximately 18% of our patient mix. We will continue to put our resources to work to help stroke and other vulnerable patients regain their independence and return to the activities that matter most to them.

Demand for inpatient rehabilitation services remains strong and is growing. We continue to invest in capacity additions to help address this underserved market. In Q3, we opened a new 50-bed hospital in Norristown, Pennsylvania and added 31 beds to existing hospitals. Through the third quarter, we opened 4 hospitals with a total of 189 beds and added 85 beds to existing hospitals.

Earlier this month, we opened 2 additional 50-bed hospitals, one in Bangor, Maine and 1 in San Antonio, Texas and added 60 beds to existing hospitals. Over the balance of the year, we intend to open 2 more hospitals with a total of 100 beds and add up to 45 beds to existing hospitals. We maintain an active pipeline of new hospital development projects while also executing on bed expansion opportunities as warranted by occupancy trends and market dynamics.

Our pipeline of announced new hospital projects with opening dates beyond 2026 currently consists of 15 hospitals with 654 beds. This includes our first 2 small format hospitals, Conroe, Texas and Richmond, Texas, both of which will be additive to our Houston market presence and serve as an exemplar of the hub-and-spoke strategy we have previously discussed.

We anticipate additional projects will be announced over the balance of the year. We also continue to expect to add 150 to 200 beds to existing hospitals in 2027. On October 1, North Carolina's repeal of its Certificate of Need law became effective. As we have previously discussed, North Carolina has highly favorable population growth and demographic characteristics and our assessment indicates a large underserved market for IRF services. We currently operate 1 hospital in North Carolina and have thus far prioritized 15 markets for development. We currently have 6 real estate parcels under contract. Now I'll turn it over to Doug.

Douglas Coltharp

Thank you, Mark, and good morning, everyone. The Q3 revenue increase of 8.9% was driven by 5.7% discharge growth and a 4% increase in net revenue per discharge. Net revenue per discharge again benefited from higher patient acuity. Bad debt expense in Q3 was 2.7%. The increase over last year is primarily due to a billing and collection disruption issue following a system conversion in Q2 of 2026.

This was a one-off issue, and we expect bad debt expense as a percent of revenue in Q4 to normalize in the recent historical range of 2% to 2.5%. Q3 Medicaid supplemental payments decreased by $10 million from Q3 '25. Recall that Q3 '25 included $10.8 million of net provider tax revenue owing largely to retroactive Medicaid supplemental payments.

In Q3 '26, we reversed $9.2 million of previously accrued supplemental payments within our other revenue category related to the anticipated approval by CMS of the Florida fiscal year 2026 Medicaid state-directed payment program. The Florida fiscal year '26 program is still pending approval from CMS. And as the fiscal year ended September 30, we deemed it appropriate to make this adjustment.

We also reversed $3.4 million of accrued provider tax expense within our other operating expenses related to the 2026 Florida program. Q3 adjusted EBITDA increased 15.5% to $346.6 million even as we absorbed an $11.5 million year-over-year decrease in net provider tax contribution. Through the first 3 quarters of 2026, the adjusted EBITDA contribution from net provider taxes was $600,000, and that compares to $18.1 million for the comparable 2025 period.

In our Q2 update, we had revised our expectation for the 2026 net provider taxes contribution to our adjusted EBITDA to approximately $10 million. This was based primarily on the Florida fiscal year 2025 Medicaid state directed payment program approved by CMS in May of 2026. Given the pending status of the fiscal year 2026 program and the related adjustments to our accruals, which I just reviewed, we now expect the 2026 net contribution to adjusted EBITDA to be approximately $3 million.

Q3 SWB per FTE increased 3.8%, in part driven by increased participation in our career ladder programs, partially offset by declines in premium labor and medical plan costs. Premium labor costs comprised of contract labor and sign-on and shift bonuses declined $3.9 million from Q3 '25 to $23.1 million. This marks 16 consecutive quarters of year-over-year reductions in premium labor spend even as capacity and patient volumes have grown substantially.

Contract labor FTEs as a percent of total FTEs was 0.9%, an improvement of 30 basis points from Q3 '25 and our lowest level since Q4 of 2020. Q3 net pre-opening and ramp-up costs were $4.9 million, flat from Q3 '25 and were $15.8 million on a year-to-date basis compared to $11 million through Q3 '25.

Based on the incurrence to date and our projection for the balance of the year, we now expect net preopening and ramp-up costs of $20 million to $24 million for 2026. Adjusted free cash flow for the first 9 months of 2026 was $634.2 million, an 8.9% increase from the comparable period in 2025.

During Q3, we repurchased approximately 495,000 shares of our common stock for a total of $57.9 million, bringing our year-to-date total share repurchase to approximately 1.91 million shares and $203.7 million. We also declared a cash dividend of $0.21 per share, which was paid earlier this month.

During Q3, we issued an incremental $100 million of senior notes as an add-on to our 5.875% notes due in 2034, bringing the total amount of that note series to $600 million. Our leverage and liquidity remained very favorable. Net leverage at quarter end was 1.8x, and we ended the quarter with approximately $870 million available on our $1 billion revolving credit facility.

As Mark mentioned, we have again raised our 2026 guidance as follows: we now expect net operating revenue of $6.45 billion to $6.5 billion, adjusted EBITDA of $1.395 billion to $1.415 billion and adjusted earnings per share of $6.23 to $6.37. The considerations underlying our guidance can be found on Page 11 of the supplemental slides. With that, we'll open the lines for Q&A.

Operator

[Operator Instructions] And we'll take our first question from Pito Chickering with Deutsche Bank.

질의응답

Pito Chickering

Nice quarter. So I know you aren't giving out 2027 guidance yet, but can you help us walk us through the known headwinds and tailwinds for next year as you do your modeling, specifically in areas like start-up losses from the hospitals opening up, managed care pricing because you just raised that this quarter, the VA penetration and then any things around labor and turnover that we should be thinking about?

Douglas Coltharp

Pito, this is Doug. I'll start on that and then ask Mark and Pat to jump in as they see appropriate. I'd say, generally speaking, we think that things are setting up for another solid year in 2027. I won't hit these in the specific order that you mentioned, but I think some things to consider. I just went through quite a few adjustments, and we did the same in Q2 regarding net provider tax impact predominantly related to the Florida '25 proposal and then '26 as well. And so we're not going to have to repeat those same accrual adjustments in 2027, and that should present some upside there.

With regard to pre-opening and ramp-up costs, we've got a comparable number of new hospitals opening next year. I would say that we would expect that number to be plus or minus $20 million. Some other things to consider is we'll anniversary the last of the 4 unit closures in late February of next year.

On the labor perspective, we're going to start to anniversary the impact of the increased career ladder participation on SWB. By the same token, and I've said this a couple of times before, at some point, we're going to start to realize diminishing returns on the reductions that we've made in premium labor, but we continue to see some opportunity there. From an overall pricing perspective, as we move into Q4 of this year, we're lapping some of the increases that we've seen based on higher patient acuity on revenue per discharge.

That's not to suggest that there isn't more room to go. But last year, in Q4, our net revenue per discharge was at 4.1%, and it stayed right around 4% for the last 4 quarters. I think those are the primary things that come to mind in terms of considerations.

Mark Tarr

Yes, Pito, it's Mark. I would just say, as we noted in my comments and as we've made a general theme now for the last couple of quarters, I mean, adding capacity is a big focus for us. So bringing on the additional projects, not only in Q4 of this year, but then as it carries over into 2027 with additional beds coming on to existing hospitals.

We're going to bring on the first small format hospital next year that we've talked about as well as additional de novos. So that will be a common theme that will go into 2027 that we've carried off from 2026.

Patrick Tuer

Pito, this is Pat. Just a couple of points on VA and then hiring and turnover. VA continues to be a big positive for us. We've now hit our sixth consecutive quarter of at least 20% growth in that segment. We hit 21% growth in Q3. That's on top of 26.4% growth in Q3 of 2025. As well as that's going, there remains a lot of upside.

There's a lot of variability between region to region and hospital to hospital in terms of capture of the VA population. So that's something our operators have done a great job with and continue to focus on. You didn't ask about this, but as I think about 2027, one of the things that I think deserves to be called out is the success that we've had in the MA admit-and-appeal strategy and how we're thinking about expanding that.

So, so far, relatively small in size. We've had 294 claims go through. 87% of those have been overturned in our favor, 81% being overturned before they go to the ALJ. So a lot to like there. And if we think about discharge growth in that population, the MA growth in those 9 markets for MA was 36%.

And then we've talked about how that has endeared us to the referral sources. They also saw total growth of about 9.5% with another benefit of 6.6% growth in Medicare. So we have just completed educating all of our hospitals on expanding that pilot for across every hospital, every payer for stroke specifically.

We've increased the number of total pilot hospitals from 9 to 13 as well. So I think we'll start to see that incrementally tick up in Q4 and certainly in 2027. And then we'll evaluate how this goes. The next 2 diagnoses that we would likely scale up through the organization is brain injury and spine, which we're having a lot of success with as well.

And then just on the hiring and turnover front, turnover did tick up slightly in Q3 to 20.7%, but that remains below our historical levels. In the 10 years from 2014 to 2023, we averaged about 24.2%. Even if you back out the COVID years, the 5 years before COVID, 2015 to 2019, we averaged about 23.2%.

So well below historical levels there. And hiring has continued to remain robust. We have more full-time net RN hires through 3 quarters of this year than we've had in the last 5 calendar years on an individual basis. The high watermark there is 2023. So again, a lot of things to be optimistic about from a workforce perspective as well as the other 2 buckets that I mentioned.

Operator

We'll take our next question from Ann Hynes with Mizuho .

Ann Hynes

So just on the capacity thought, I know that your capacity is running very high and I know -- I think you said like 35% of your hospitals may be running at 85% capacity. Can you update that stat for us? And when do you think those capacity constraints could be freed to really accelerate same-store discharge growth?

Douglas Coltharp

Yes. So it is a factor. It's not the only factor. And generally speaking, when you're running at high system-wide occupancy rates, that's a really high-class problem. Specifically, we called out a cohort of hospitals that have been running at greater than 90% capacity with an average capacity -- an average occupancy of 95%.

And so in Q1, we identified that there were 65 hospitals in that cohort. In Q2, the number dropped to 60. And in Q3, the number dropped further to 58. Across those 3 quarters, there have been 49 hospitals that have been present in that cohort for each of those 3 quarters. 19 of those will have bed additions between now and the end of fiscal year 2027. So that will help greatly in that regard.

And as Mark mentioned earlier, we're excited about the addition of the small format hospitals that's really going to help us address those in some markets where there are physical limitations on our ability to expand.

Patrick Tuer

Ann, this is Pat. Just in addition to what Doug has shared and what Mark has mentioned as well, we're really excited about our development pipeline. Both our development team, our operators and others at the home office have done a lot of work thinking about capacity expansions and how do we continue to take advantage of the demographic tailwind that is in front of us. And our pipeline from a de novo and small format hospital perspective is larger than it's ever been.

And we're working hard to figure out how do we -- we guide to 6 to 10 hospitals a year with inclusive of North Carolina. We think we can get to the top of that range and potentially in the outer years, be above that range. So we're working towards that and really excited about the pipeline, both from a de novo and small format perspective.

Douglas Coltharp

And the demand is there to support it. If you look just at the counties in which Encompass Health has a presence, from September of 2025 to 2026 in those counties, there were almost 0.5 million more Medicare beneficiaries.

And roughly 50% of those, a little bit more than 50% were fee-for-service versus Medicare Advantage. So you've got an underserved population that continues to grow, and I know you've heard the mantra from us frequently, but the demographic tailwinds are still very much there.

Operator

We'll take our next question from Andrew Mok with Barclays.

Andrew Mok

Just wanted to follow up on the managed care pricing. The guidance assumption increased 125 basis points at the midpoint to a new range of 3.5% to 4%. Would love to hear what's driving that increase. Is the admit and appeal strategy part of that? And can you also confirm that, that's unit pricing only and does not include shifts in acuity?

Douglas Coltharp

It does include shift in acuity, and it's benefiting from that. The biggest driver there is something that Pat mentioned before, which is that is -- in that category, we include our VA DCM volume, and that's been growing consistently at north of 20%. And as a reminder, that pays at the fee-for-service rate.

So the reason that we adjusted it up for the full year is because of the favorable performance we've had for the first 3 quarters of the year. Medicare Advantage is not included in that bucket. And again, that has skewed upward in acuity in part because of the more stringent pre-authorization that we've been facing and the fact that we've been able to replace some of the lower volume -- some of the lower acuity patients there with the higher acuity, specifically the stroke example that Pat gave earlier.

Andrew Mok

Got it. Okay. That's helpful. And then maybe just a follow-up on the small format hospitals. You mentioned that you have 2 in the pipeline, but I believe only one is expected to open in 2027. Can you confirm that one is still the expectation? And just given the smaller format and presumably faster speed to open, why isn't that a bigger number in 2027? Why can't you accelerate that?

Douglas Coltharp

So I can confirm that our expectation is that one will open in late '27. The best explanation I can give you on why we're not moving faster right now is that small format hospitals are not only new to us, they're new to the communities in which we're introducing those, which have their own licensing and permitting aspects to them.

And so in some of those instances, it doesn't fit -- the small format hospital doesn't fit neatly within the definition of either an acute care hospital or more of a subsidiary type of arrangement. And so we're having to spend a little bit more time on the front end through the permitting and licensing processes so that there's a greater understanding of what requirements really need to be contained within the remote location versus those that are provided by the host location.

I think the good news is really on a state-by-state basis, once you have cracked the code the initial time, the template is set, and we'll be able to go much faster. And it's that aspect of it that gives us a lot of confidence that as we get rolling here, we're going to be able to accelerate that pipeline pretty significantly into 2028 and 2029. The design is there. We're confident in the design. We've got the capacity with our general contractors, and there's no capital constraint either.

Patrick Tuer

I would add to that, that just from a market identification standpoint, our operators and development team have identified about 200 locations where this potentially could happen. As Doug mentioned, we really think that we're going to be in a position to ramp this up in 2028 and 2029. I think we would all be collectively disappointed if we're opening less than 6 of those a year by that point.

Operator

We will take our next question from Matthew Gillmor with KeyBanc.

Matthew Gillmor

I wanted to ask about the RCD expansion. I think you indicated 75 more hospitals will be subject to RCD in 2027. And at least when we look at the CMS reports, it seemed like the affirmation rate with Palmetto had been improving. Just wanted to see if you had any comments in terms of what to expect as that gets rolled out to additional hospitals next year.

Douglas Coltharp

Yes. So I'll start by saying that with regard to the expansion into Jurisdiction JJ, which does include 75 more of our hospitals, we are having ongoing discussions with both Palmetto and CMS to understand specifically how it's going to work.

Our greatest concern is whether or not Palmetto is going to be able to handle this administratively. Palmetto's involvement in RCD thus far has been limited to the state of Alabama and 7 of our hospitals are included there. But the expansion into Jurisdiction JJ is going to increase the volume that they're going to have to process by more than 10x.

It's a requirement that during cycle 1, which will -- is slated to begin on January 1 and extend through June 30, all providers will be on 100% prepayment claim review. There's no option out of that in cycle 1. So that's going to be a real burden on Palmetto, and we just want a greater understanding as to how they're going to be able to process that.

That said, to the extent that we progress through cycle 1, and hospitals exceed the target affirmation rate of 80%, which we would have a high degree of confidence based on our experience to date, they will. And beginning July 1, one of the options we would have is to move from the 100% prepayment claim review to a 5% spot check.

We have just moved into cycle 2 for the 24 hospitals that we have in Texas, where we performed very well and above the target affirmation rate, and we've made the decision to move to the 5% spot check there. And I think it's our anticipation that we'll avail ourselves of the same opportunity as it arises in other RCD markets.

Matthew Gillmor

Great. That's helpful. And then maybe just one follow-up. On the bad debt expense, you called out some impact from, I think, a system conversion. I was just hoping you could explain what happened there.

Douglas Coltharp

Yes. So really about 2/3 of the increase was due to the system conversion. I'll probably give you more detail than you would want. But in Q2, we converted our patient billing system from a legacy system that was called Patcom to the Oracle module. And we did so because Patcom was essentially being sunsetted and the Oracle module has enhanced functionality as well as greater comparability with our Fusion ERP.

When we initiated the cutover, the pending claims that were left in the legacy system required a more manual processing. And at the same time, we were shifting some of our resources in that area over to processing claims under the new system. As these claims were pending, they became subject to our aging-based reserve methodology.

By the end of Q3, we were essentially caught up on our Medicare billing and collections, but the queue had not been cleared out for our managed care and our Medicare Advantage. And those payers typically run at a higher bad debt expense than Medicare fee-for-service, and they also generally require higher patient co-pays, and we can't bill for the co-pays until the payers process our claims. So it creates this backlog.

Now we expect that queue to be fully cleared by the end of the year. And it is important to note that all claims since conversion are processing through the Oracle module without an issue. So this is really a onetime situation.

Operator

We'll take our next question from Whit Mayo with Leerink.

Morgan McCarthy

It's Morgan McCarthy on for Whit. So your unit cost per discharge were effectively flat on a year-over-year basis. Is there anything to call out whether it's this year or in prior years related to provider taxes or any other cost items that might skew that metric?

Douglas Coltharp

Yes. So the net impact from provider taxes was actually going to be a negative on that. But where we had some gains, again, SWB was very favorable. That was driven by lower group medical expense in the quarter and then also just by the lower overall turnover. EPOB was favorable for the quarter. Length of stay was favorable for the quarter.

I will note that we had a benefit in supplies. You may recall that in Q3 of '25, we called out the fact that we had advanced some purchases of supplies in advance of the Fusion conversion in order to avoid any disruption. And obviously, we didn't have to replicate this year. But generally, when you've got a pricing increase in the 4% range, the flow-through and the efficiency there tends to be high.

Operator

And we'll take our next question from Ryan Langston with TD Cowen.

Ryan Langston

You had some really nice acuity pickup recently that's carried through into the third quarter. I guess, is that acuity lift a durable opportunity into 2027? And might RCD expansion impact the acuity of the patient transfers from the acute care hospitals?

Patrick Tuer

I'll start there, and -- acuity can shift or RC mix can shift on a quarter-over-quarter basis, but we do think that some of the trends that we're seeing are sustainable. We talked last quarter about the shift in acuity, and I'll call out a couple of diagnosis categories where we saw some really nice growth that are driving that again.

We had 9.3% growth in our neuro RIC, 5.1% growth in stroke, 5.7% in brain injury, and then major trauma was up 10.3%. Some of those had a softer comp last year. But even if you look at it on a 2-year stack from a same-store basis, brain injury was up 9.8%, neuro up 8.5%, stroke and major trauma up 5.7%. And that mix is gaining because lower acuity conditions like lower extremity joint replacements are down.

So in Q3, same-store lower extremity joint replacements were down 5.3%. On a total store basis, they were down 0.7%, and we were able to backfill that volume with those higher acuity conditions. Not only are we seeing an increase in -- from a RIC perspective, the percent of patients that come to us with comorbid conditions, it also continues to increase. And then we're getting the benefit on the pricing side as well from the outcomes that we're seeing. So even though we're seeing higher acuity conditions, we continue to do a better job of getting those patients home, and that has a favorable pickup on the pricing line.

Douglas Coltharp

We don't anticipate that RCD expansion will have any impact on patient acuity. We believe we are admitting appropriate patients and providing the appropriate documentation for those patients.

Ryan Langston

Got it. And then sorry if I missed this in the supplemental payment commentary, but is there any update on the potential tax waiver program in Florida? And can you remind us if there's any impact, plus or minus, to guidance for 2026?

Douglas Coltharp

Yes. So we went through the fact that we reversed the year-to-date accrual through the first 3 quarters. And that is because the fiscal year '26 ended on October 1 for Florida without a decision, positive or negative from CMS on the proposal set forth by Florida.

The proposal set forth would include waivers for many of our hospitals in that state. If that were to come through in the fourth quarter, it has a potential favorable increase to EBITDA of about $8 million, which would be the sum of the roughly $5.5 million net impact that we reversed in our Q3 earnings plus the pickup we would get for Q4. As we look into 2027, again, if it's approved with the waivers in it as submitted, that would be a positive. And again, on a year-over-year basis, we took that $11.5 million hit related to the fiscal year '25 Florida plan in the second quarter, and we're not anticipating that we would replicate that.

Operator

We'll move next to Joanna Gajuk with Bank of America.

Joanna Gajuk

So I guess, first on the small format hospitals, it was very exciting, I guess, type of developments there. But can you remind us -- I couldn't remember whether you talk about the returns on these projects versus, say, your typical 40, 50-bed hospital?

Because I guess you're leveraging some of the local costs in there, right? So can you remind us how that progresses, I guess, when you have a small format versus just a regular hospital because of return?

Douglas Coltharp

Yes, absolutely. So we've been targeting and realizing returns, IRRs on our de novo program in the mid-teens, and that's based on maintaining a cost per bed, which we feel some degree of confidence in moving forward of roughly $1.25 million per bed. Bed expansions to existing hospitals offer the greatest leverage opportunity and then also the highest returns. We are at 25% or higher with regard to the IRR on bed expansions at existing hospitals, and the average cost per bed there tends to be right around $850,000.

The small format hospitals are going to fall right in between. We're estimating the cost per bed on those will be right at $1 million, and we're targeting an IRR of about 20%. You identified the ability to get some efficiencies by sharing certain components of the administrative staff with the host hospital.

And as a result, whereas we run on a corporate-wide basis an EPOB of just under 3.4x, we think there's an opportunity for the small format hospitals to have an EPOB below 3x, and that's a highly sensitive metric with regard to the P&L and therefore, the flow-through to returns.

Joanna Gajuk

Okay. That is great. And I guess the other question that I had in terms of this acuity-driven pricing, it seems like it's very sustainable there, and thanks for breaking out the volume growth by the different categories.

So anything to call out that would suggest that somehow things could slow down into next year? I know it's volatile quarter-to-quarter, but if we think say the next 12 months or so, anything that would say, hey, like things should slow down or change versus your trajectory?

Douglas Coltharp

Other than to recall that at least some of the increase in acuity that's flowing through in the pricing growth is attributable to the trends that we've been seeing within Medicare Advantage. And the increase in pre-authorization denials that skewed us towards a higher acuity within our MA book of business first became really prevalent in Q4 of '25.

So if you looked at Q4 of '25, we had a 4.1% net revenue per discharge. Our MA discount for that quarter, it tends to widen out from Q3 to Q4 because MA price increases on a calendar basis and fee-for-service increases on a fiscal year basis was 2%. And it's -- so as we anniversary those higher increases, even if acuity is maintained at the current levels, the year-over-year pricing change is going to be less pronounced.

Operator

We'll take our next question from Brian Tanquilut with Jefferies.

Brian Tanquilut

So maybe, Doug, my first question, contract FTE this quarter showed some pretty good improvement. And I know in Q2, you said that the gains were getting smaller. So just curious what you're seeing there in terms of on the permanent side, hiring, retention and the career ladder grads that you're putting out there and how that's translating into contract labor.

Douglas Coltharp

I'm going to toss that one over to Pat because it's something that he spends a lot of time focused on.

Patrick Tuer

Yes. And Doug continues to challenge us on the operations side by talking about the diminished returns that we're going to see in reducing contract labor and premium pay. And there is a truth to that. But this was another really strong quarter, and I highlighted some of the hiring and turnover dynamics earlier in the call. But we still have -- if you look at contract labor, extra shift sign-on overtime and you normalize that by a per patient day basis, we still have a couple of dozen hospitals that are over $100 per patient day in spend.

So there still is juice for us to squeeze there, and we've had a lot of success working on those higher spend hospitals to bring that number down. Again, just to reinforce what I said earlier, net RN hires and therapy hires has not been better in years. Even if turnover ticked up a bit, the hiring dynamics have certainly overcome that and turnover on a historical basis is still very strong.

From a ladder perspective, we are up to 55% of eligible nurses are on the ladder. That represents about 31% of all of our full-time nurses being on the ladder. They have to be here for a certain period of time to move up into the ladder. So there's some upside there.

Again, we had a big bolus in 2026 of the ladder, and we're going to anniversary some of that. So any of that upside within the ladder, we'll be able to take those dollars and not be as pronounced as they were in 2026. But our largest bucket of opportunity is noncertified non-laddered nurses, which represents about 60% of our full-time nurses.

And again, we have some variation from region to region that we're working to improve upon. And I think if we can continue to do that, we're going to continue to see improvements not only in turnover reduction in the premium pay buckets, but also in the continued sustainability of the higher acuity patients that we've been able to bring in.

Mark Tarr

Brian, you've heard us say before relative to contract labor, we've given our operators the green light. If they've got the volume and need to have contract labor to accommodate that volume, they need to go ahead, and we'll take the hit on a short term until we can work it back out of the system. But we are not being throttled on our volume because of the focus on eliminating contract labor.

Brian Tanquilut

Maybe my follow-up, just as I think about the hospitals that you've opened in the first half of the year, how are they tracking in terms of hitting breakeven in your typical ramp? I mean, just curious how this class of new openings are performing.

Douglas Coltharp

So remember, we're heavily skewed towards the back end of the year with 4 hospitals, 4 of the 8 opening up in Q4. That said, we think that these are tracking in accordance with our recent historical performance.

And just as a reminder there, generally, what we have been seeing is that our de novo hospitals are achieving a 4-wall positive EBITDA by about month 6, and they're climbing over a 70% occupancy by about month 10. And then they're achieving what we would suggest is full maturity and typically qualifying for a bed addition sometime between year 3 and year 4. So we have no reason to expect that the performance of the current class is going to be any different from that recent historical.

Operator

We'll take our next question from A.J. Rice with UBS.

Albert Rice

Yes. First question on the discharge growth on the same-store basis, there's been a lot of focus on that. I wondered if you would just offer us any comments. I know -- I think you mentioned that you had the final 4 closures will anniversary in February of those. And then you've obviously had the pacing on the new facilities.

Anything to call out in the way to think about same-store discharge growth over the next number of quarters here, where there's any challenges or where there's some easy comps? I know you got a long-term target of 4% to 6% growth on that.

Douglas Coltharp

Yes. So actually, I think our total discharge growth from '23 to '27, the target that we put out there was 6% to 8%. We didn't break that down between new store and same store. This won't surprise you, A.J., but I'm going to start with my usual disclaimer that we think it is increasingly less relevant to think about the distinction between new store and same-store that what really matters most is total discharge growth and the capital that's required to generate it.

Having now said my piece with regard to the disclaimer, I'm going to take you through 5 factors that we think are relevant to looking at same-store. The first that you mentioned was the impact from the 4 unit consolidations. That impact on a net basis, we estimate for Q3 was about 40 basis points. That's down from 70 basis points in Q2 and from 90 basis points in Q1, and that will be fully lapped in Q1 '27.

And as a reminder, the reduction in the volumes related to those unit closures carried no impact to EBITDA. Second is something that I mentioned earlier, which is that cohort of high occupancy hospitals, 65% above 90% in Q1, 60% above 90% in Q2, 58% above 90% in Q3, 49 hospitals consistent through all 3 of those quarters, 19 of those will have bed additions coming on board prior to the end of the year in '27.

The third factor I would mention was the change that we saw in MA pre-authorization denials beginning in Q3 -- or excuse me, in Q4 of last year. If you look at total MA discharges in Q3, it actually declined 1.1%. Adjusted for the unit closures, which were disproportionately high in Medicare Advantage for the patient mix, especially the sole SNF unit that we closed, we would have been up 1%, still not the height of our aspirations.

As Pat mentioned earlier, in the 9 admit and appeal pilot markets for the quarter, total discharge growth was up 9.3%. So what we've demonstrated is that pilot is working. And as Pat outlined, we're looking forward to extending that across stroke in all of our hospitals and then bringing more hospitals into the fold from a pilot perspective. In terms of bed additions and new hospitals, as we mentioned previously, bed additions in 2026 were also heavily weighted towards the second half of the year.

Q3 benefited from only 54 beds added to existing hospitals in the first half of '26. And also, we only had one de novo, and that was Loganville, Georgia that moved from new store to same-store in Q3. I'll note that we have 90 beds moving into same-store in Q4 and another 150 in Q1 of '27.

And then something we haven't talked about a lot, but it's evident, I think, to some degree in our overall patient mix is there is some impact that is happening across the [indiscernible] team markets. And so in Q3, we saw knee and hip replacement actually declined 3.6%. These are small categories for us and cardiac declined about 0.7%.

Now not all teams markets are reacting the same. And in those markets, we're having a lot of success substituting higher acuity and/or VA CCN patients for these lower acuity patients that may be subject for team [indiscernible]. It may not be a one-for-one change from a volume perspective, what we're seeing in those markets is that the move to the higher acuity patients and the move to the VA CCN patients is generating higher revenue and EBITDA.

Albert Rice

Okay. That's great. I would -- maybe as my follow-up, just to ask, I know you're now down to 1.8x net leverage. I think you previously said that it wouldn't necessarily make sense to go below 2x. Should we think of capital deployment from here, leaning into share repurchases, dividends? Anything else, any comment you want to make along those lines?

Douglas Coltharp

Yes. I think the capital allocation framework is going to be relatively consistent. You'll probably see modest occasional or periodic increases in the dividend. So that's not going to consume a lot of that capacity. Pat mentioned earlier that as we think about an accelerating pipeline for both small format hospitals and for de novo openings, particularly with the attractiveness of North Carolina is just an example that we're likely to see our discretionary CapEx begin to increase, and that's still going to leave capacity while maintaining a very favorable leverage target for increased share repurchase activity. So we like the combination of those things.

Operator

We'll take our next question from Jared Haase with William Blair.

Jared Haase

Maybe I'll ask one on the current mix of your beds between single occupancy and double. I know you kind of had this shift towards more single over the last couple of years. Just wanted to get an update on where that stands today? And then based on what you have in the pipeline, where you think that could trend over the next couple of years?

Douglas Coltharp

Yes. So at the end of the third quarter, we were at 58%. That compares, if you go all the way back to 2020 at 41%. So 58% were private. All of -- essentially all of the capacity that we're bringing on in all 3 modalities, bed additions, de novos and small format hospitals is going to be 100% single occupancy. So that number will continue to push up.

And we'll get some benefit of that here in the fourth quarter because of the number of bed additions and new hospitals that we have coming on board. So that number will be higher when we report it for Q4.

Jared Haase

Okay. Very helpful. And then I appreciate all the details on the Medicare Advantage admit-and-appeal strategy. I realize it's still relatively early with the pilots. But just given the success you've seen so far and then your thinking around how you can expand that to other conditions and other hospitals across the portfolio.

I guess when we think about the impact to the model, are there any guardrails that you would sort of frame for us in terms of what the actual net impact could be on conversion rate or I guess, ultimately, volume growth within that cohort over the next several years?

Douglas Coltharp

Well, generally speaking, we think it's positive, a, because we're anniversarying the more challenging pre-authorization from the MA plans that began in Q4 of last year, and this has proven to be an effective tool because even beyond what we were experiencing in these categories with regard to denial rates, pre that dip in Q4 of last year, we're seeing higher success rates. All that said, it's not going to happen in a vacuum. And so we believe it is a tailwind in terms of quantifying it. That's yet to be determined.

Patrick Tuer

Jared, this is Pat. We're in the process now of -- we've added resources since we started the pilot. We're adding a good number of FTEs that are going to help us as we scale this throughout the organization. But we're putting the structure in place to be able to go a little bigger here.

Operator

We will take our next question from Raj Kumar with Stephens.

Raj Kumar

Maybe just wanted to touch back on RCD. As I kind of look at the Alabama cycle-through reports, kind of the claims activity coming down by 25% relative to the pre-RCD baseline, but kind of looking at you guys' results, fee-for-service is still pretty strong.

So would love to kind of reconcile kind of your experience in that kind of Alabama program across these 3 cycles. And more specifically, I guess, kind of where your initial affirmation rates are kind of maybe where your appeal rates are as well? And maybe helping us extrapolate to this more expanded RCD program. Any details there would be helpful.

Douglas Coltharp

Well, it's hard to extrapolate any of our experience across the expanded program because Palmetto, in particular, has never been asked to handle this volume of claims. And so we don't know if it's going to be the same reviewers. We don't know if it's going to be under the direction of the same medical director. We don't know whether they're going to be using subcontractors. We don't know if the program is ultimately going to be phased in, et cetera.

What we do have a high degree of confidence in is that there's -- that we are admitting the right kind of patients, and we are providing the appropriate documentation. And again, as this extension begins on -- assuming it begins across all of these 75 hospitals on January 1, we will be prepared administratively to do our part -- and the target affirmation rate in cycle 1 is going to be 80%, and we have a very high degree of confidence that all of our hospitals are going to get over that 80% target affirmation rate.

And if they do beginning July 1, we can move to a 5% spot check. That is not something that we have experienced to date because to this point, either because we were in cycle 1 in the other states that just came out, which was a requirement like California and Texas or because we elected to stay for various reasons on 100% prepayment claim review in Alabama, we haven't had experience with the 5% spot check. But the math will tell you that the impact is going to be less and the administrative burden will be less.

And so again, we think if there's volatility in the bad debt number that arises out of the rollout to the 75 incremental hospitals, it's going to be contained and it's likely going to be contained in the first half of the year. It's important to note, none of the coverage requirements, none of the patient criteria under RCD are any different than they have been under the audit programs that we've been subject to for an extended period of time and that have informed our historical bad debt in this recent range of 2% to 2.5%.

So there's no reason to believe that things settle in, that we're going to settle in at a bad debt number that differs in any material way from that which we've experienced historically.

Raj Kumar

Got it. Maybe just following up on that. I guess when I think about maybe some of the more independent IRFs and maybe some behavioral changes around maybe not appealing or not admitting IRF-eligible patients that might be on the fringe of eligibility.

I guess, have you maybe experienced any market share gain dynamics from that or any favorability as I kind of think about kind of your administrative working power versus maybe an independent mom-and-pop IRF?

Douglas Coltharp

We don't think we're admitting patients who are on the fringe of eligibility. We think that the patients that we admit clearly meet IRF admission requirements.

Patrick Tuer

Yes. This is Pat. I would just add, I sit on the Board of AMRPA, which is the Trade Association for Inpatient Rehab Providers. And I think not only Encompass, but the other providers within AMRPA have all done a really nice job with RCD. And it hasn't shifted our admission practices.

I mean, we are taking the same patients that we did before and to my knowledge, the other providers are as well. So I think if anything, administrative burden aside, we're proud of the fact that this has demonstrated such a strong record of compliance within our company and the industry.

Operator

At this time, there are no further questions in queue. I will now turn the meeting back to Mark Miller for any additional or closing remarks.

Mark Miller

Thank you, operator. If anyone has additional questions, please call me at (205) 970-5860. Thank you again for joining today's call.

Operator

Thank you. This brings us to the end of today's meeting. We appreciate your time and participation. You may now disconnect.